Treatments for Translocation RCC Require Novel Therapeutic Targets
Immune checkpoint inhibitors have been associated with improved outcomes for patients with metastatic translocation renal cell carcinoma; however, novel therapies and therapeutic targets are needed for patients within this histologic subset.
Source: onclive.com